AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24931951 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug therapy
Number of subjects: 0
Study 24931951 — intervention group
Group type: COMPARATOR
Intervention: monotherapy
Number of subjects: 0
Study 22383748 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic blacks with CKD not requiring dialysis
Number of subjects: 1497
Study 22383748 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic whites with CKD not requiring dialysis
Number of subjects: 1497
Study 22383748 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks with CKD not requiring dialysis
Number of subjects: 1497
Study 22383748 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks with CKD and ESRD
Number of subjects: 1497
Study 19438129 — intervention group
Group type: EXPERIMENTAL
Intervention: 2700 CGy in 5 fractions (one week)
Number of subjects: 300
Study 19438129 — intervention group
Group type: EXPERIMENTAL
Intervention: 3500 CGy in 10 fractions (2 weeks)
Number of subjects: 300
Study 19438129 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 CGy in 15 fractions (3 weeks)
Number of subjects: 300
Study 17486919 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil pTCI
Number of subjects: 28
Study 17486919 — intervention group
Group type: COMPARATOR
Intervention: remifentanil eTCI
Number of subjects: 28
Study 14990551 — intervention group
Group type: EXPERIMENTAL
Intervention: High-force eccentric contractions
Number of subjects: 9
Study 12235451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Number of subjects: 40
Study 12235451 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 40
Study 9521221 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (Lipitor) at dosages of 10 to 80 mg/d
Number of subjects: 4271
Study 7986114 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy of CDDP+VDS
Number of subjects: 0
Study 7986114 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 7986114 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP and 5‐FU
Number of subjects: 0
Study 7986114 — intervention group
Group type: COMPARATOR
Intervention: Surgery + postoperative chemotherapy with CDDP+5‐FU
Number of subjects: 0
Study 7986114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo‐radiotherapy
Number of subjects: 0
Study 2736615 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous group (I)
Number of subjects: 120
Study 2736615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal group (II)
Number of subjects: 120
Study 4923653 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (10 weeks treatment)
Number of subjects: 34
Study 31222468 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature for overall survival (OS)
Number of subjects: 110
Study 31222468 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature for progression-free survival (PFS)
Number of subjects: 110
Study 31222468 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature for local control (LC)
Number of subjects: 110
Study 29208255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice cream test
Number of subjects: 104
Study 29208255 — intervention group
Group type: COMPARATOR
Intervention: 75-g OGTT
Number of subjects: 104
Study 29208255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice cream test and 75-g OGTT
Number of subjects: 104
Study 26323697 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher heart rate (71-117 beats/min)
Number of subjects: 5042
Study 26323697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SDNN (1.70-13.30 ms)
Number of subjects: 5042
Study 23614585 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 691
Study 23614585 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing
Number of subjects: 691
Study 21223551 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (trial medication)
Number of subjects: 28
Study 21223551 — intervention group
Group type: COMPARATOR
Intervention: N/A (participants who declined to participate)
Number of subjects: 28
Study 19127470 — intervention group
Group type: EXPERIMENTAL
Intervention: Permutation test following Pocock‐Simon's covariate‐adaptive randomization
Number of subjects: 0
Study 19127470 — intervention group
Group type: COMPARATOR
Intervention: Traditional population‐based tests
Number of subjects: 0
Study 16829885 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of the Modified Dental Anxiety Scale
Number of subjects: 1004
Study 16829885 — intervention group
Group type: COMPARATOR
Intervention: Completion of the state anxiety assessment only
Number of subjects: 1004
Study 12729348 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of BCG vaccination
Number of subjects: 71341
Study 12729348 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of BCG vaccination
Number of subjects: 71341
Study 11079287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention with home blood pressure monitoring
Number of subjects: 36
Study 11079287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 11079287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 36
Study 9296529 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 3 IU/m2 per day for group 1 (n=6)
Number of subjects: 17
Study 9296529 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 4.5 IU/m2 per day for group 2 (n=6)
Number of subjects: 17
Study 9296529 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 3 IU/m2 per day in the 1st year and 4.5 IU/m2 per day thereafter for group 3 (n=5)
Number of subjects: 17
Study 9296529 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 4 years (14 children) and 5 years (8 children)
Number of subjects: 17
Study 8326054 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couple therapy
Number of subjects: 0
Study 8326054 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 0
Study 8326054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of behavioral couple therapy and cognitive-behavioral therapy
Number of subjects: 0
Study 8326054 — intervention group
Group type: EXPERIMENTAL
Intervention: Husbands' facilitative behavior
Number of subjects: 0
Study 3709072 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple short term prescribed diet
Number of subjects: 12
Study 3709072 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 12
Study 29855838 — intervention group
Group type: EXPERIMENTAL
Intervention: Doula-home-visiting services
Number of subjects: 312
Study 29855838 — intervention group
Group type: COMPARATOR
Intervention: Case management
Number of subjects: 312
Study 27398703 — intervention group
Group type: EXPERIMENTAL
Intervention: GWG above IOM guidelines
Number of subjects: 293
Study 27398703 — intervention group
Group type: COMPARATOR
Intervention: GWG within IOM guidelines
Number of subjects: 293
Study 24857719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing food 40 times before swallowing
Number of subjects: 15
Study 24857719 — intervention group
Group type: COMPARATOR
Intervention: Chewing food 15 times before swallowing
Number of subjects: 15
Study 23158712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus methylprednisolone
Number of subjects: 156
Study 23158712 — intervention group
Group type: COMPARATOR
Intervention: Control (methylprednisolone alone)
Number of subjects: 156
Study 20937977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.5 mg/d
Number of subjects: 8556
Study 20937977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.25 mg/d
Number of subjects: 8556
Study 20937977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8556
Study 18341545 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 127
Study 18341545 — intervention group
Group type: COMPARATOR
Intervention: Group treatment
Number of subjects: 127
Study 16253807 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained subjects; Distribution volume of [11C]TMSX in myocardium: 3.6+/‐0.3 ml g(‐1); Triceps brachii muscle: 1.7+/‐0.3 ml g(‐1)
Number of subjects: 10
Study 16253807 — intervention group
Group type: COMPARATOR
Intervention: Untrained subjects; Distribution volume of [11C]TMSX in myocardium: 3.1+/‐0.4 ml g(‐1); Triceps brachii muscle: 1.2+/‐0.2 ml g(‐1)
Number of subjects: 10
Study 12142983 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-based digital radiography
Number of subjects: 25
Study 12142983 — intervention group
Group type: COMPARATOR
Intervention: Conventional screen-film radiography
Number of subjects: 25
Study 12142983 — intervention group
Group type: COMPARATOR
Intervention: Comparison of selenium-based digital radiography and conventional screen-film radiography
Number of subjects: 25
Study 10433668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient handwashing education model
Number of subjects: 0
Study 10433668 — intervention group
Group type: COMPARATOR
Intervention: Control (no patient education)
Number of subjects: 0
Study 8519712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine
Number of subjects: 180
Study 8519712 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 180
Study 8519712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized mepivacaine
Number of subjects: 180
Study 8519712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized bupivacaine
Number of subjects: 180
Study 1694294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (34 mg/kg)
Number of subjects: 20
Study 1694294 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (1.75 g/kg)
Number of subjects: 20
Study 1694294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (9.7 mg/kg)
Number of subjects: 20
Study 795779 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol
Number of subjects: 47
Study 795779 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 47
Study 31924158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice with cyclosporine (100 mg cyclosporine + 500 ml pomegranate juice)
Number of subjects: 14
Study 31924158 — intervention group
Group type: COMPARATOR
Intervention: Water with cyclosporine (100 mg cyclosporine + 500 ml water)
Number of subjects: 14
Study 29619799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, ketogenic diet (LC; <50 g/day and <10% of energy from carbohydrates)
Number of subjects: 16
Study 29619799 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (HC; 6-10 g/kg/day carbohydrate)
Number of subjects: 16
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Folic Acid (FA)
Number of subjects: 18775
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Iron + Folic Acid (IFA)
Number of subjects: 18775
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Multiple Micronutrients (MMN)
Number of subjects: 18775
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Folic Acid (FA) before 12 weeks
Number of subjects: 18775
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Iron + Folic Acid (IFA) before 12 weeks
Number of subjects: 18775
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Multiple Micronutrients (MMN) before 12 weeks
Number of subjects: 18775
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Folic Acid (FA) after 12 weeks
Number of subjects: 18775
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Iron + Folic Acid (IFA) after 12 weeks
Number of subjects: 18775
Study 28472219 — intervention group
Group type: COMPARATOR
Intervention: Multiple Micronutrients (MMN) after 12 weeks
Number of subjects: 18775
Study 25229605 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Active Stretching (SAS)
Number of subjects: 36
Study 25229605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Active Stretching (DAS)
Number of subjects: 36
Study 25229605 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study 24001080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) midazolam
Number of subjects: 0
Study 24001080 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) lorazepam
Number of subjects: 0
Study 22204002 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing during total knee arthroplasty
Number of subjects: 1715
Study 22204002 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing during total knee arthroplasty
Number of subjects: 1715
Study 22204002 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 1715
Study 22204002 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing
Number of subjects: 1715
Study 18302621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue scraping
Number of subjects: 72
Study 18302621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Number of subjects: 72
Study 18302621 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction/chlorhexidine + cetyl pyridinium gargling
Number of subjects: 72
Study 16569890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (100 mg BID) with fosamprenavir (700 mg BID)
Number of subjects: 0
Study 16569890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (100 mg BID) with amprenavir (600 mg BID)
Number of subjects: 0
Study 16569890 — intervention group
Group type: COMPARATOR
Intervention: Fosamprenavir (700 mg BID) alone
Number of subjects: 0
Study 16569890 — intervention group
Group type: COMPARATOR
Intervention: Amprenavir (600 mg BID) alone
Number of subjects: 0
Study 12525383 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment
Number of subjects: 117
Study 12525383 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study
Number of subjects: 117
Study 11185675 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.375 mg plus 8 mg rosiglitazone
Number of subjects: 0
Study 11185675 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.375 mg plus matching placebo
Number of subjects: 0
Study 8874587 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 40
Study 8874587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1316077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily for 10-14 days
Number of subjects: 150
Study 1316077 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg every 12 hours for 10-14 days
Number of subjects: 150
Study 2867576 — intervention group
Group type: EXPERIMENTAL
Intervention: IV naloxone
Number of subjects: 24
Study 2867576 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 24
Study 31678959 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound‐guided ESPB with 0.5% ropivacaine
Number of subjects: 82
Study 31678959 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 82
Study 30577847 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the peer-review network (active intervention, n=18)
Number of subjects: 38
Study 30577847 — intervention group
Group type: COMPARATOR
Intervention: Control arm (delayed participation in the network, n=20)
Number of subjects: 38
Study 26969218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vdrive™ with V‐Loop™ system (remote navigation)
Number of subjects: 120
Study 26969218 — intervention group
Group type: COMPARATOR
Intervention: Manual navigation (control)
Number of subjects: 120
Study 23421896 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated advisor
Number of subjects: 148
Study 23421896 — intervention group
Group type: COMPARATOR
Intervention: Human advisor
Number of subjects: 148
Study 22154198 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment for 6 months, titrated to 40 mg/d
Number of subjects: 56
Study 22154198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin treatment)
Number of subjects: 56
Study 21198251 — intervention group
Group type: EXPERIMENTAL
Intervention: Training alone
Number of subjects: 0
Study 21198251 — intervention group
Group type: COMPARATOR
Intervention: Task-switching dyads
Number of subjects: 0
Study 21198251 — intervention group
Group type: COMPARATOR
Intervention: Interdependent dyads
Number of subjects: 0
Study 21198251 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-prompted metacognitive activity in interdependent dyads
Number of subjects: 0
Study 21198251 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-prompted metacognitive activity in task-switching dyads
Number of subjects: 0
Study 16708003 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback and educational outreach
Number of subjects: 1078
Study 16708003 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach
Number of subjects: 1078
Study 16708003 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials alone
Number of subjects: 1078
Study 12854103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 200
Study 12854103 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 200
Study 10686268 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 2-sec trains of 20 Hz stimulation with 58-sec intervals; delivered at 80% motor threshold over the left dorsolateral prefrontal cortex)
Number of subjects: 20
Study 10686268 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (similar conditions with the coil elevated and angled 45 degrees tangentially to the scalp)
Number of subjects: 20
Study 10686268 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 20
Study 10686268 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study 9052303 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion group (Group I, n = 6)
Number of subjects: 15
Study 9052303 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection group (Group II, n = 9)
Number of subjects: 15
Study 8246028 — intervention group
Group type: COMPARATOR
Intervention: OND (ondansetron)
Number of subjects: 44
Study 8246028 — intervention group
Group type: EXPERIMENTAL
Intervention: ODC (ondansetron, dexamethasone, chlorpromazine)
Number of subjects: 44
Study 3512534 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine up to 200 mg/day (mean = 130 mg/day)
Number of subjects: 62
Study 3512534 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weekly therapist‐assisted in vivo exposure sessions (flooding)
Number of subjects: 62
Study 3512534 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus flooding
Number of subjects: 62
Study 3512534 — intervention group
Group type: COMPARATOR
Intervention: Systematic therapeutic instructions for self‐directed in vivo exposure (programmed practice)
Number of subjects: 62
Study 30875548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent and ambiguous evidence
Number of subjects: 363
Study 30875548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitive inference explanations
Number of subjects: 363
Study 30875548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconclusive evidence
Number of subjects: 363
Study 30875548 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving accuracy
Number of subjects: 363
Study 29704557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mabfilin and Fabfilin molecules
Number of subjects: 0
Study 24141101 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention problems in both grades (persistent attention problems)
Number of subjects: 0
Study 24141101 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention problems in first grade only
Number of subjects: 0
Study 24141101 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention problems emerging in second grade
Number of subjects: 0
Study 24141101 — intervention group
Group type: COMPARATOR
Intervention: Comparison children
Number of subjects: 0
Study 25315237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 0
Study 25315237 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study 22825900 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 16
Study 22825900 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized iloprost
Number of subjects: 16
Study 19793929 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 42
Study 17074329 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearblue Easy Fertility Monitor (CEFM)
Number of subjects: 653
Study 17074329 — intervention group
Group type: COMPARATOR
Intervention: Control (no CEFM)
Number of subjects: 653
Study 16282697 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day from 2 days after surgery
Number of subjects: 24
Study 16282697 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 24
Study 14662211 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (intravenous methylprednisolone 125 mg followed by oral prednisone taper: 40 mg for 1 day, 20 mg for 3 days, 10 mg for 3 days, 5 mg for 7 days)
Number of subjects: 126
Study 14662211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing regimen)
Number of subjects: 126
Study 10711607 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pedicle flaps (DPF)
Number of subjects: 29
Study 10711607 — intervention group
Group type: EXPERIMENTAL
Intervention: Apically positioned flaps (APF)
Number of subjects: 29
Study 10711607 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival grafts (FGG)
Number of subjects: 29
Study 10711607 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated sites)
Number of subjects: 29
Study 10711607 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative periodontal parameters
Number of subjects: 29
Study 9377140 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel stick
Number of subjects: 27
Study 9377140 — intervention group
Group type: COMPARATOR
Intervention: Venepuncture
Number of subjects: 27
Study 7967324 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 64